Press Releases

Press Releases

View all news
Voronoi Files Securities Registration Statement for KOSDAQ Listing
2022.01.24
⚫ KRW 2 trillion in license-out deals... 11 pipeline programs

Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies, is expected to become the 'first company listed under the unicorn special track' on the KOSDAQ market.

Voronoi Inc. announced on the 24th that it has submitted a securities registration statement to the Financial Services Commission for listing on the KOSDAQ market.

Prior to submitting the securities registration statement, Voronoi Inc. held a board meeting on the 21st and resolved to conduct a paid-in capital increase. Voronoi Inc. is the first company to receive approval of its preliminary listing review using the special track for companies with excellent market valuations (the unicorn special track), which was newly established on the KOSDAQ in April of last year. Under the unicorn special track, a company with an expected market capitalization of KRW 500 billion or more becomes eligible to apply for a KOSDAQ preliminary listing review if it receives a grade of A or higher from just one professional evaluation institution.

Voronoi Inc.'s public offering will consist entirely of newly issued shares, with 2,000,000 shares offered, bringing the total number of shares after listing to 13,333,949. The desired offering price range is KRW 50,000 to 65,000 per share, resulting in a market capitalization at the offering price of KRW 666.7 billion to 866.7 billion.

Voronoi Inc.'s book building for institutional investors will take place on February 24–25, and the public subscription on March 7–8. The schedule may change depending on the effective date of the securities registration statement. Korea Investment & Securities and Mirae Asset Securities are the joint lead underwriters.

Voronoi Inc. develops targeted therapies that treat disease by binding to and inhibiting the function of kinases, proteins that transmit signals inside and outside cells. Just as traffic becomes paralyzed when a traffic light malfunctions and stays on continuously, disease occurs when the signal regulation of kinases fails to function normally due to causes such as mutations. Voronoi Inc. possesses technology for creating precise therapies that bind preferentially to the disease-causing kinases among the many kinases with similar molecular structures, and that can penetrate the blood-brain barrier (BBB).

By combining artificial intelligence (AI) models with its world-class capability to accumulate wet-lab experimental data, Voronoi Inc. has shortened the time required to derive drug candidates to 1 to 1.5 years, about one third of the usual period. On this basis, the company has completed four license-out deals since 2020, three overseas and one domestic, and currently has 11 pipeline programs.

In particular, the cumulative total milestone value of its three global license-out deals amounts to USD 1,790.5 million, or approximately KRW 2.1 trillion: an EGFR Exon20 INS-targeting non-small cell lung cancer therapy in October 2020 (NASDAQ-listed ORIC Pharmaceuticals), a DYRK1A therapy for autoimmune and neurodegenerative diseases in August 2021 (NASDAQ-listed Brickell Biotech), and an MPS1-targeting breast cancer and other solid tumor therapy in November 2021 (Pyramid Biosciences of the U.S.).

Hyuntae Kim, CEO of the Management Division of Voronoi Inc., said, "Our goal is to maximize the likelihood of FDA marketing approval by licensing out multiple pipeline programs to global pharmaceutical companies with experience in obtaining U.S. FDA approval."